A major breakthrough in the treatment of premature babies with chronic lung disease could save them from life-long health problems, Australian scientists say.

There are up to 60 per cent of pre-term babies develop bronchopulmonary dysplasia (BPD).  This causes damage to lung tissue and prevents normal lung growth, this is due to being exposed to life-saving respiratory support.  This disease could leave babies with a lifetime of health concerns.  

However, the researchers at Hudson Institute of Medical Research said two types of anti-inflammatory drugs already used on children could stop the development of bronchopulmonary dysplasia (BPD) in pre-term babies and the next step would be to start introducing clinical trials.  

“The treatment we are working on and we want to develop would actually give hope to those babies affected and those babies that are born pre-term and have a rough start to life, so we would be able to give them a brighter future.”

See the full published article here




Supporting neonatal research

One of our core objectives is supporting neonatal research so that the care of babies is enhanced and the long term outcomes are better understood. To learn more about some of the world leading research occuring in New Zealand, head to staging.littlemiraclestrust.org.nz/research